← All trials
NCT03517631
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 27, 2018
- Primary completion
- Jul 15, 2018
- Completion date
- Jan 20, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 6
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Fudan UniversityLead sponsor
- Fudan UniversityReponsible party - principal investigator
- Kanglin Biotech (Hangzhou) Co. LTDCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.